Autolus Therapeutics PLC (AUTL)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| CEO: | Christian M. Itin |
| Employees: | 330 |
| Web site: | autolus.com |
|
THE MEDIAWORKS, 191 WOOD LANE, LONDON, X0, W12 7FP
44 20 3829 6230
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Autolus Therapeutics plc develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trials for adult ALL. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development.
Please log in first to see chart